Patents Assigned to Taipei Veterans General Hospital
-
Patent number: 9033952Abstract: A puncture needle device, comprising a light source assembly, an optic fiber assembly, an ejection assembly, and a puncture needle assembly, wherein the light source assembly comprises a light source sleeve configured with a light source, the optic fiber assembly comprises an optic fiber sleeve configured with an optic fiber, the ejection assembly comprises an ejection sleeve configured with an ejection spring, and the puncture needle assembly comprises a puncture needle with a catheter.Type: GrantFiled: September 24, 2013Date of Patent: May 19, 2015Assignee: TAIPEI VETERANS GENERAL HOSPITALInventor: Pin-Tarng Chen
-
Patent number: 9023341Abstract: The present invention relates to a novel injectable delivery system for stem cell therapy, which comprises a thermo-sensitive amphiphlic chitosan nanogel. Therefore, the invention provides a method for repairing a tissue damage of a subject using the amphiphlic chitosan nanogel served as a carrier for delivering the stem cells to the damaged tissue. This invention also provides a method for sustaining the growth of stem cells using the amphiphlic chitosan nanogel served as a niche or scaffold.Type: GrantFiled: February 19, 2013Date of Patent: May 5, 2015Assignee: Taipei Veterans General HospitalInventors: Shih-Hwa Chiou, Dean-Mo Liu
-
Patent number: 8975465Abstract: A diaper having wetness detectors, a system thereof and a wetness detecting method are adapted to detect the excreting status of an animal. The diaper includes a first set of contacts and a second set of contacts which are constituted by conductive material. The first set of contacts and the second set of contacts are respectively disposed on proximal and distal area of the diaper corresponding to the excretory organ of the animal. A detecting circuit detects the electrical property of the first set of contacts and the second set of contacts and then determines the excretion status of the animal to be a reference for a caregiver.Type: GrantFiled: September 23, 2011Date of Patent: March 10, 2015Assignees: Industrial Technology Research Institute, National Yang-Ming University, Taipei Veterans General HospitalInventors: Ruey-Shyan Hong, Hung-Wen Chang, Chu-Hsuan Chen, Su-Jan Lee, Biing-Shiun Huang, Shwn-Jen Lee
-
Patent number: 8962587Abstract: The present invention provides a method for decreasing the level of methylation of Oct4 promoter in a target cell, comprising transfecting the target cell with the combination of Oct4 cDNA and SirT1 cDNA. The invention also provides a method for inducing cytoprotective responses of a target cell, comprising transfecting the target cell with the combination of Oct4 cDNA and SirT1 cDNA. The invention further provides a pharmaceutical composition comprising Oct4 cDNA and SirT1 cDNA, or a polynucleotide comprising Oct4 cDNA and SirT1 cDNA.Type: GrantFiled: August 31, 2012Date of Patent: February 24, 2015Assignee: Taipei Veterans General HospitalInventors: Shih-Hwa Chiou, Jong-Yuh Cherng
-
Publication number: 20150011972Abstract: The present invention provides a puncture needle device, comprising a light source assembly, an optic fiber assembly, an ejection assembly, and a puncture needle assembly, wherein the light source assembly comprises a light source sleeve configured with a light source, the optic fiber assembly comprises an optic fiber sleeve configured with an optic fiber, the ejection assembly comprises an ejection sleeve configured with an ejection spring, and the puncture needle assembly comprises a puncture needle with a catheter.Type: ApplicationFiled: September 24, 2013Publication date: January 8, 2015Applicant: Taipei Veterans General HospitalInventor: Pin-Tarng Chen
-
Patent number: 8906679Abstract: A composite comprising a stem cell; a biodegradable layer, which can provide an environment for the stem cell to grow and to differentiate, and; a N-isopropylacrylamide (NIPAAm), which can polymerize with the biodegradable layer and possess the temperature-responsive character for easy stripping. The present invention further provides a method for treating a patient with a skin defect, consisting of (a) providing said patient with a composite consisting of a N-isopropylacrylamide (NIPAAm) layer polymerized with a biodegradable layer containing gelatin and a layer of polypropylene (PP) non-woven, wherein a bone marrow derived mononuclear cell with CD45 negative and glycophorin A negative is cultivating on the biodegradable layer; (b) covering said composite on the skin defect of the patient; and (c) treating the composite with water below 25° C. to strip off the layer of polypropylene (PP) non-woven.Type: GrantFiled: April 17, 2013Date of Patent: December 9, 2014Assignee: Taipei Veterans General HospitalInventors: Shih-Hwa Chiou, Cherng-Kang Perng, Han-Tzo Lin, Yi-Ping Yang
-
Patent number: 8846633Abstract: The present invention provides a method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells comprising delivering miR145 to the cancer or tumor cells, particularly brain tumor and head and neck cancer cells. The invention further provides a pharmaceutical composition comprising miR145 and a method for treating brain tumor and/or head and neck cancer comprising administration of miR145 to a subject in need thereof.Type: GrantFiled: November 7, 2012Date of Patent: September 30, 2014Assignee: Taipei Veterans General HospitalInventors: Shih-Hwa Chiou, Han-Shui Hsu, Jong-Yuh Cherng
-
Publication number: 20140187860Abstract: A guidable endoscope is described, which includes a rigid guiding part, a bending controllable part, a rigid endoscope body and a handle part. The rigid guiding part has a first end and a second end opposite to each other. The bending controllable part has a first end and a second end opposite to each other. The first end of the bending controllable part is directly connected to the second end of the rigid guiding part. The rigid endoscope body has a first end and a second end opposite to each other. The first end of the rigid endoscope body is directly connected to the second end of the bending controllable part, and the bending controllable part can be bent relative to the rigid guiding part or the rigid endoscope body. The handle part is connected to the second end of the rigid endoscope body.Type: ApplicationFiled: December 27, 2013Publication date: July 3, 2014Applicants: METAL INDUSTRIES RESEARCH & DEVELOPMENT CENTRE, TAIPEI VETERANS GENERAL HOSPITALInventors: Tung-Chieh YANG, Yi-Hsiu HUANG, Tsung-Chih YU
-
Publication number: 20140142106Abstract: The present invention provides a method for treating, preventing or reducing peritoneal fibrosis comprising administering to a subject in need thereof a pharmacologically effective dose of a type I cannabinoid receptor (CB1R) antagonist or a type II cannabinoid receptor (CB2R) agonist. Also provided is a dialysis fluid for treating, preventing or reducing peritoneal fibrosis comprising electrolytes, an osmotic agent, a physiologically acceptable pH solution, and a pharmacologically effective dose of a CB1R antagonist or a CB2R agonist.Type: ApplicationFiled: January 11, 2013Publication date: May 22, 2014Applicant: TAIPEI VETERANS GENERAL HOSPITALInventors: Chih-Yu Yang, An-Hang Yang
-
Publication number: 20140105934Abstract: The present invention pertains to a new approach for the treatment of infectious and malignant diseases. The present invention provides new DNA and protein vaccines for the treatment of infectious and malignant diseases through enhancing immune response.Type: ApplicationFiled: November 13, 2013Publication date: April 17, 2014Applicant: Taipei Veterans General HospitalInventors: Keng-Li Lan, Yi-Sheng Shih, Keng-Hsin Lan
-
Publication number: 20140093486Abstract: The present invention relates to a novel method for preparing induced pluripotent stem cells (iPSCs) by introducing three genes, Oct3/4, Sox2, and Parp1, into somatic cells. The present invention also relates to the iPSCs produced by the aforementioned method. Also provided is a method of rejuvenating cells by use of a PARylated protein or an enzyme with PARylation activity. Further provided is a method for inducing the secretion of interferon-? inducible protein-10 (IP-10) comprising administering to a subject in need thereof an effective amount of iPSCs or iPSC-CM.Type: ApplicationFiled: October 1, 2013Publication date: April 3, 2014Applicant: Taipei Veterans General HospitalInventors: SHIH-HWA CHIOU, YUEH CHIEN, GUANG-YUH CHIOU, YI-PING YANG
-
Patent number: 8609625Abstract: The present invention pertains to a new approach for the treatment of infectious and malignant diseases. The present invention provides new DNA and protein vaccines for the treatment of infectious and malignant diseases through enhancing immune response.Type: GrantFiled: June 25, 2012Date of Patent: December 17, 2013Assignee: Taipei Veterans General HospitalInventors: Keng-Li Lan, Yi-Sheng Shih, Keng-Hsin Lan
-
Publication number: 20130238092Abstract: A composite comprising a stem cell; a biodegradable layer, which can provide an environment for the stem cell to grow and to differentiate, and; a N-isopropylacrylamide (NIPAAm), which can polymerize with the biodegradable layer and possess the temperature-responsive character for easy stripping. The present invention further provides a method for treating a patient with a skin defect, consisting of (a) providing said patient with a composite consisting of a N-isopropylacrylamide (NIPAAm) layer polymerized with a biodegradable layer containing gelatin and a layer of polypropylene (PP) non-woven, wherein a bone marrow derived mononuclear cell with CD45 negative and glycophorin A negative is cultivating on the biodegradable layer; (b) covering said composite on the skin defect of the patient; and (c) treating the composite with water below 25° C. to strip off the layer of polypropylene (PP) non-woven.Type: ApplicationFiled: April 17, 2013Publication date: September 12, 2013Applicant: Taipei Veterans General HospitalInventors: Shih-Hwa Chiou, Cherng-Kang Perng, Han-Tzo Lin, Yi-Ping Yang
-
Publication number: 20130230495Abstract: The present invention relates to a novel injectable delivery system for stem cell therapy, which comprises a thermo-sensitive amphiphlic chitosan nanogel. Therefore, the invention provides a method for repairing a tissue damage of a subject using the amphiphlic chitosan nanogel served as a carrier for delivering the stem cells to the damaged tissue. This invention also provides a method for sustaining the growth of stem cells using the amphiphlic chitosan nanogel served as a niche or scaffold.Type: ApplicationFiled: February 19, 2013Publication date: September 5, 2013Applicant: Taipei Veterans General HospitalInventors: Shih-Hwa CHIOU, Dean-Mo LIU
-
Publication number: 20130226312Abstract: The preset invention relates to a novel cell graft suitable for transplantation or cell therapy and the use thereof for treating diseases. In particular, the graft provided herein overcomes concomitant rejection when transplanted onto a patient, which is especially beneficial for the condition where allogeneic cells are used. Also provided is a process for preparing such grafts by culturing at least one cell type under hypoxic or anoxic conditions.Type: ApplicationFiled: December 28, 2012Publication date: August 29, 2013Applicant: TAIPEI VETERANS GENERAL HOSPITALInventor: Taipei Veterans General Hospital
-
Patent number: 8481094Abstract: The present invention provides a method of treating neural injury, e.g., spinal cord injury (SCI), or enhancing recovery from the neural injury with silymarin or silybin.Type: GrantFiled: April 5, 2010Date of Patent: July 9, 2013Assignee: Taipei Veterans General HospitalInventors: Henrich Cheng, May-Jywan Tsai
-
Patent number: 8470597Abstract: A composite comprising a stem cell; a biodegradable layer, which can provide an environment for the stem cell to grow and to differentiate, and; a N-isopropylacrylamide (NIPAAm), which can polymerize with the biodegradable layer and possess the temperature-responsive character for easy stripping. The present invention further provides a method for treating a patient with a skin defect, consisting of (a) providing said patient with a composite consisting of a N-isopropylacrylamide (NIPAAm) layer polymerized with a biodegradable layer containing gelatin and a layer of polypropylene (PP) non-woven, wherein a bone marrow derived mononuclear cell with CD45 negative and glycophorin A negative is cultivating on the biodegradable layer; (b) covering said composite on the skin defect of the patient; and (c) treating the composite with water below 25° C. to strip off the layer of polypropylene (PP) non-woven.Type: GrantFiled: January 18, 2011Date of Patent: June 25, 2013Assignee: Taipei Veterans General HospitalInventors: Shih-Hwa Chiou, Cherng-Kang Perng, Han-Tzo Lin, Yi-Ping Yang
-
Publication number: 20130115299Abstract: The present invention provides a method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells comprising delivering miR145 to the cancer or tumor cells, particularly brain tumor and head and neck cancer cells. The invention further provides a pharmaceutical composition comprising miR145 and a method for treating brain tumor and/or head and neck cancer comprising administration of miR145 to a subject in need thereof.Type: ApplicationFiled: November 7, 2012Publication date: May 9, 2013Applicant: TAIPEI VETERANS GENERAL HOSPITALInventor: Taipei Veterans General Hospital
-
Publication number: 20130108691Abstract: The present invention is based on the findings that a novel function for miR142-3p in the regulation of Sox2, adenylyl cyclase 9 (AC9), and CD133 expressions, and consequently the overall stemness of recurrent GBM cells as well as CSCs, and that miR142-3p modulated tumor-initiating properties in recurrent GBM. The present invention consequently supports the development of novel miRNA-based strategies for brain tumor treatment.Type: ApplicationFiled: December 21, 2012Publication date: May 2, 2013Applicant: TAIPEI VETERANS GENERAL HOSPITALInventor: Taipei Veterans General Hospital
-
Patent number: 8404437Abstract: The present invention is based on the findings that a novel function for miR142-3p in the regulation of Sox2, adenylyl cyclase 9 (AC9), and CD133 expressions, and consequently the overall stemness of recurrent GBM cells as well as CSCs, and that miR142-3p modulated tumor-initiating properties in recurrent GBM. The present invention consequently supports the development of novel miRNA-based strategies for brain tumor treatment.Type: GrantFiled: March 29, 2011Date of Patent: March 26, 2013Assignee: Taipei Veterans General HospitalInventors: Shih-Hwa Chiou, Guang-Yuh Chiou